[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629195":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":42,"collaborators":20,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":20,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":20,"enrollmentInfo":53,"targetDuration":20,"studyType":56,"phases":57,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Zoledronic Acid","EXPERIMENTAL","Participants in this arm will receive a total of 4 doses of Zoledronic acid. Following the first dose, there is a 4-week safety observation period before proceeding with subsequent doses every 4 weeks. The total follow-up period for efficacy and safety assessment is 24 weeks.",[13],"Drug: zoledronic acid",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","zoledronic acid","Zoledronic acid will be administered at a dose of 4 mg via a standardized intravenous (IV) infusion lasting no less than 15 minutes. To ensure safety, the initial dose is followed by a 4-week rigorous observation period. If the treatment is well-tolerated without significant adverse events, subsequent doses will be given every 28 days for a total of 4 cycles. Patients will be closely monitored for serum calcium levels and renal function (eGFR) throughout the intervention period to mitigate potential risks associated with bisphosphonate therapy.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Xin Zhao, MD","CONTACT","8613702041366","zhaoxin@ihcams.ac.cn",[28],{"facility":29,"status":30,"city":31,"state":20,"zip":20,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Institute of Hematology & Blood Diseases Hospital","RECRUITING","Tianjin","China","CN",{"type":35,"coordinates":36},"Point",[37,38],117.17667,39.14222,{"lat":38,"lon":37},[41],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":43,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100629195","phase-1-zoledronic-acid-treatment-in-patients-with-congenital-dyserythropoietic-anemia-100629195",false,"NCT07471516","Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia","Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia: An Exploratory Study","Inclusion Criteria:\n\n* Age ≥ 18 years, regardless of gender.\n* Diagnosis of Congenital Dyserythropoietic Anemia (CDA) based on clinical presentation, laboratory tests, and family investigation, with the presence of RBM28 mutation and\u002For increased vacuolization within nucleated red blood cells under light microscopy of bone marrow.\n* Presence of anemia (Hemoglobin \\\u003C 100 g\u002FL at screening) or transfusion dependence (defined as an average transfusion interval of \\\u003C 8 weeks within the past 3 months).\n* Performance status is acceptable (ECOG score 0-2).\n* Normal renal function (estimated glomerular filtration rate, eGFR ≥ 60 mL\u002Fmin\u002F1.73m²).\n* Serum calcium levels within the normal range.\n* Female patients of childbearing potential must have a negative pregnancy test before enrollment and agree to use effective contraception during the study and for 3 months after completion.\n* The patient and\u002For guardian voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Known hypersensitivity to bisphosphonates or any of their excipients.\n* Severe periodontal disease or a recent history (within 6 months) of osteonecrosis of the jaw.\n* Hypocalcemia.\n* Pregnant or lactating women.\n* Currently receiving other experimental drug treatments that may affect erythropoiesis (e.g., Luspatercept).\n* Active, uncontrolled systemic infection.\n* Severe cardiac, pulmonary, or hepatic dysfunction, as judged by the investigator to be unsuitable for participation in the study","ALL","18 Years",{"count":54,"type":55},2,"ESTIMATED","INTERVENTIONAL",[58,59],"PHASE1","PHASE2","Background:\n\nCongenital Dyserythropoietic Anemia (CDA) is a group of rare hereditary blood disorders characterized by ineffective erythropoiesis, leading to chronic anemia and organ damage. Current treatment options are very limited, mainly relying on regular blood transfusions, which can cause severe complications over time. Our laboratory research and animal models suggest that Zoledronic acid, a medication commonly used for bone health, may improve ineffective erythropoiesis.\n\nPurpose:\n\nThe purpose of this exploratory study is to evaluate the efficacy and safety of Zoledronic acid in adult patients with CDA who do not have other effective treatment options. The primary goal is to see if this treatment can increase hemoglobin levels and reduce the need for blood transfusions.\n\nStudy Design:\n\nThis is a prospective, single-center, single-arm study. Participants will receive an initial intravenous dose (4 mg) of Zoledronic acid. After a 4-week observation period to ensure safety, participants will receive additional doses every 4 weeks for a total of 4 doses. Researchers will monitor hemoglobin levels, transfusion frequency, spleen size, and overall quality of life over a period of 12 to 24 weeks.",[62],"Congenital Dyserythropoietic Anemia (CDA)",[64,9],"Congenital Dyserythropoietic Anemia","2026-03-12",{"date":67,"type":68},"2026-03-13","ACTUAL",{"date":70,"type":68},"2026-02-25",{"date":72,"type":55},"2027-08-12",{"name":5,"class":6},1]